M&R Capital Management Inc. Has $2.01 Million Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

M&R Capital Management Inc. lowered its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,065 shares of the exchange traded fund’s stock after selling 950 shares during the period. M&R Capital Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $2,012,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Morgan Stanley boosted its holdings in SPDR S&P Biotech ETF by 18.2% in the 1st quarter. Morgan Stanley now owns 9,002,902 shares of the exchange traded fund’s stock valued at $697,184,000 after purchasing an additional 1,387,956 shares during the period. tru Independence LLC boosted its holdings in SPDR S&P Biotech ETF by 234.6% in the 1st quarter. tru Independence LLC now owns 378,743 shares of the exchange traded fund’s stock valued at $21,475,000 after purchasing an additional 265,559 shares during the period. Kellogg W K Foundation Trust bought a new stake in SPDR S&P Biotech ETF in the 2nd quarter valued at about $28,125,000. Papp L Roy & Associates lifted its holdings in shares of SPDR S&P Biotech ETF by 0.4% during the 2nd quarter. Papp L Roy & Associates now owns 224,430 shares of the exchange traded fund’s stock worth $25,125,000 after acquiring an additional 785 shares during the period. Finally, Eaton Vance Management lifted its holdings in shares of SPDR S&P Biotech ETF by 21.0% during the 1st quarter. Eaton Vance Management now owns 223,903 shares of the exchange traded fund’s stock worth $17,339,000 after acquiring an additional 38,911 shares during the period.

Shares of SPDR S&P Biotech ETF stock traded up $1.40 on Thursday, reaching $112.83. 3,816,713 shares of the stock were exchanged, compared to its average volume of 6,481,810. The firm’s 50 day moving average is $109.92 and its 200-day moving average is $101.88. SPDR S&P Biotech ETF has a one year low of $62.94 and a one year high of $121.06.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: Why do companies issue monthly dividends?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.